Quantcast

Latest Erythropoietin Stories

2011-07-11 06:30:00

NES-ZIONA, Israel, July 11, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity...

2011-06-24 11:14:00

HORSHAM, Pa., June 24, 2011 /PRNewswire/ -- Janssen Products, LP, formerly Centocor Ortho Biotech Products, L.P., today announced updated prescribing information for PROCRIT® (Epoetin alfa) when used to treat anemia associated with chronic kidney disease (CKD) as part of a U.S. Food and Drug Administration (FDA)-approved class-wide update for erythropoiesis-stimulating agents (ESAs). The updates include modifications to the Boxed Warning, Warnings and Precautions,...

2011-06-24 10:51:00

THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), in patients with chronic kidney disease (CKD). The modified language, including changes to the Boxed Warning, provides important new...

2011-06-24 10:47:00

Cites increased risk of cardiovascular events when used to treat chronic kidney disease SILVER SPRING, Md., June 24, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death. (Logo:...

2011-06-20 06:30:00

NES-ZIONA, Israel, June 20, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that its paediatric investigation plan for clinical development of its long-acting human growth hormone (hGH-CTP) has been accepted for review by the Paediatric Committee of the European Medicines Agency (EMA). Following promising efficacy and safety interim results in its ongoing Phase II trial of hGH-CTP in growth hormone-deficient adults, PROLOR is now actively pursuing development...

2011-06-13 06:30:00

NES-ZIONA, Israel, June 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that the U.S. Patent and Trademark Office (PTO) has allowed a new patent for the company's veterinary version of its long-acting CTP-enhanced non-human growth hormone (NhGH-CTP). The patent covers the composition of PROLOR's proprietary pharmaceutical non-human growth hormone as well as certain associated methods of use for veterinary applications. "This new patent covering...

2011-06-06 06:00:00

NES-ZIONA, Israel, June 6, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG). The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with oxyntomodulin injected twice daily. It was conducted using a state-of-the-art animal model specifically...

2011-06-01 08:09:00

Making prescription drugs affordable EDMONTON, June 1, 2011 /PRNewswire/ - Compass Biotechnologies (COBI:OB) is a product-oriented, specialty biopharmaceutical company focused on developing products for multi-billion dollar markets. The Company is pleased to announce the first product to be sourced from its manufacturing partner (PanGen of South Korea) will be a class of protein product known as Erythropoietins (EPO). Erythropoietins had global sales of approximately $32...

2011-05-23 06:30:00

NES-ZIONA, Israel, May 23, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that its proprietary CTP and Reversible PEGylation platforms for extending the longevity of most proteins, peptides and small molecules will be highlighted today in a presentation at the joint meeting of the Summer Neuropeptide Conference and The European Neuropeptide Club (ENC). The joint conference,...

2011-05-18 17:05:00

THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago. These studies include data from the XGEVA® (denosumab), Vectibix® (panitumumab), ganitumab (AMG 479) and AMG 386 programs. "Amgen researchers around the globe are passionate about developing new...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.